Compare Abeona Therapeutics Inc (ABEO) vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $16.6. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | PDBC | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | — |
52-Week High | $7.23 | $18.91 |
52-Week Low | $4.17 | $12.90 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
PDBC trades at $16.32, up 2.84% today, with a bullish technical signal despite mixed moving averages and oscillators. The ETF has delivered strong returns, including 37% gains since March 2024, outperforming the S&P 500, though recent commodity momentum has softened. Its structure avoids K-1 tax forms, attracting $4.6 billion in assets as an inflation hedge.
Outlook remains cautiously optimistic given commodity price volatility and geopolitical risks. Opportunities include continued inflation hedging demand, but risks involve oil price declines and unpredictable annual distributions. Recent downgrade to hold reflects near-term caution amid supply disruptions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →
